Opportunities for Industry
Please visit the following links for more information on industry participation in the special type 1 diabetes funding program:
-
TrialNet: a network of clinical centers, investigators, and core support facilities in the U.S. and Canada that supports the development and implementation of clinical trials of agents to slow the progression of type 1 diabetes in new-onset patients and to prevent type 1 diabetes in those at-risk of developing the disease.
-
Immune Tolerance Network: an international consortium that evaluates promising tolerogenic treatment regimens in four clinical areas: islet transplantation, kidney transplantation, autoimmune diseases, and asthma and allergy diseases.
-
DirecNet: The mission of DirecNet is to investigate the potential use of glucose monitoring technology and its impact on the management of type 1 diabetes in children.
-
Diabetic Retinopathy Clinical Research Network (DRCR.net): The mission of DRCR.net is to facilitate the conduct of multi-center clinical research of diabetic retinopathy, diabetic macular edema, and associated conditions.
-
Trans-Institute Angiogenesis Research Program (TARP): This trans-NIH program is encouraging and facilitating the study of the underlying mechanisms controlling blood vessel growth and development.
-
Non-Human Primate Transplantation Tolerance Cooperative Study Group (NHPCSG): The NHPCSG, a multi-institution consortium, was established to evaluate the safety and efficacy of novel donor-specific, tolerance induction therapies in non-human primate (NHP) models of kidney and islet transplantation. The program also supports research into the immunological mechanisms of tolerance induction and development of surrogate markers for the induction, maintenance, and loss of tolerance.
- Juvenile Diabetes Research Foundation International (JDRF) industry funding opportunities: please visit http://www.jdrf.org/index.cfm@P1page_id=103238
- NIH Resources for SBIR/STTR
NIH SBIR/STTR Program | NIDDK SBIR/STTR Program and Staff Contacts